NOVAVAX INC 8-K

What Happened

• On February 26, 2026, Novavax, Inc. (NVAX) announced its financial results for the quarter ended December 31, 2025 via a press release.
• The announcement was reported on Form 8‑K under Item 2.02 (Results of Operations and Financial Condition) and the press release is attached as Exhibit 99.1 to the filing.

Key Details

• Filing date: February 26, 2026 (Form 8‑K, Item 2.02).
• Reporting period: Quarter ended December 31, 2025 (referred to as the company’s third quarter results in the filing).
• Exhibit included: Press release dated February 26, 2026 (Exhibit 99.1).
• Technical exhibit: Cover Page Interactive Data File in Inline XBRL (Exhibit 104).

Why It Matters

• This 8‑K is the company’s official public disclosure of its quarterly earnings/financial results; investors should review the attached press release for revenue, earnings, cash position, and any commentary on operations or guidance.
• Quarterly results can affect Novavax’s stock price and investor sentiment; the press release (and upcoming quarterly filings such as the 10‑Q) will provide fuller financial detail needed to assess performance and outlook.